Total Payments
$4.9M
2024 Payments
$791,460
Companies
42
Transactions
3,127
Medicare Patients
184
Medicare Billing
$34,255
Payment Breakdown by Category
Other$2.3M (47.3%)
Consulting$1.8M (36.5%)
Research$431,930 (8.9%)
Travel$325,064 (6.7%)
Food & Beverage$27,644 (0.6%)
Education$25.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.2M | 530 | 44.9% |
| Consulting Fee | $1.8M | 649 | 36.5% |
| Unspecified | $431,930 | 432 | 8.9% |
| Travel and Lodging | $325,064 | 883 | 6.7% |
| Honoraria | $109,836 | 35 | 2.3% |
| Food and Beverage | $27,644 | 593 | 0.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $4,500 | 1 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,145 | 1 | 0.0% |
| Grant | $2,000 | 2 | 0.0% |
| Education | $25.00 | 1 | 0.0% |
Payments by Type
General
$4.4M
2,695 transactions
Research
$431,930
432 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $932,393 | 437 | $0 (2024) |
| ABBVIE INC. | $820,200 | 549 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $777,306 | 556 | $0 (2024) |
| PFIZER INC. | $683,802 | 452 | $0 (2024) |
| Eli Lilly and Company | $274,404 | 137 | $0 (2024) |
| LEO Pharma AS | $238,910 | 150 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $222,260 | 97 | $0 (2024) |
| LEO Pharma Inc. | $190,432 | 93 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $180,288 | 236 | $0 (2024) |
| Lilly USA, LLC | $125,867 | 96 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $791,460 | 521 | ABBVIE INC. ($221,389) |
| 2023 | $830,023 | 532 | AbbVie Inc. ($191,013) |
| 2022 | $916,971 | 595 | ABBVIE INC. ($276,679) |
| 2021 | $673,128 | 326 | PFIZER INC. ($179,912) |
| 2020 | $374,558 | 219 | PFIZER INC. ($70,780) |
| 2019 | $421,460 | 319 | Regeneron Healthcare Solutions, Inc. ($118,641) |
| 2018 | $457,124 | 325 | GENZYME CORPORATION ($134,737) |
| 2017 | $389,177 | 290 | GENZYME CORPORATION ($159,669) |
All Payment Transactions
3,127 individual payment records from CMS Open Payments — Page 1 of 126
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/28/2024 | SANOFI-AVENTIS U.S. LLC | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,393.00 | General |
| Category: Immunology | ||||||
| 12/27/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $232.82 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/21/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $184.34 | General |
| Category: Dermatology | ||||||
| 12/20/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $2,387.50 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/19/2024 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $6.71 | General |
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,250.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | LEO Pharma Inc. | — | Consulting Fee | Cash or cash equivalent | $5,882.50 | General |
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $794.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | PFIZER INC. | CIBINQO (Drug) | Travel and Lodging | In-kind items and services | $436.13 | General |
| Category: Inflammation & Immunology | ||||||
| 12/13/2024 | PFIZER INC. | LITFULO (Drug) | Travel and Lodging | In-kind items and services | $436.12 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $397.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $397.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $32.82 | General |
| Category: Dermatology | ||||||
| 12/11/2024 | PFIZER INC. | CIBINQO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,250.00 | General |
| Category: Inflammation & Immunology | ||||||
| 12/10/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| 12/10/2024 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $1,350.00 | General |
| 12/09/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $5,950.00 | General |
| 12/06/2024 | Amgen Inc. | Enbrel (Biological) | Consulting Fee | Cash or cash equivalent | $1,830.00 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $11,938.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $3,820.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $426.45 | General |
| 12/04/2024 | Galderma Laboratories, L.P. | — | Consulting Fee | Cash or cash equivalent | $11,850.00 | General |
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,775.00 | General |
| Category: Immunology | ||||||
| 12/04/2024 | GENZYME CORPORATION | DUPIXENT (Biological), DUPIXENT | Travel and Lodging | In-kind items and services | $604.75 | General |
| Category: Immunology | ||||||
| 12/04/2024 | PFIZER INC. | CIBINQO (Drug) | Travel and Lodging | In-kind items and services | $258.39 | General |
| Category: Inflammation & Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $165,730 | 154 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $80,955 | 117 |
| CRISABOROLE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $26,270 | 21 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $23,545 | 3 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $19,625 | 1 |
| M16-048 | AbbVie, Inc. | $13,535 | 4 |
| DOSE-RANGING TRIAL TO EVALUATE DELGOCITINIB CREAM 1, 3, 8, AND 20 MGG COMPARED TO DELGOCITINIB CREAM VEHICLE OVER AN 8-WEEK TREATMENT PERIOD IN ADULT SUBJECTS WITH ATOPIC DERMATITIS. | LEO Pharma AS | $10,887 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB ADMINISTERED CONCOMITANTLY WITH TOPICAL CORTICOSTEROIDS IN PATIENTS, >=6 YEARS TO <12 YEARS OF AGE, WITH SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $10,798 | 22 |
| A PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <6 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $9,537 | 8 |
| TRALOKINUMAB TRIAL IN ADJUNCT SETTING | LEO Pharma AS | $8,212 | 5 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONG-TERM SAFETY OF DUPILUMAB IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $7,808 | 17 |
| Dupixent Clinical Development Program | Regeneron Pharmaceuticals, Inc. | $6,137 | 9 |
| HEALTH ECONOMICS AND OUTCOMES RESEARCH (HEOR) | Regeneron Pharmaceuticals, Inc. | $5,347 | 6 |
| TRALOKINUMAB: TRIAL IN ADJUNCT SETTING | LEO Pharma AS | $4,703 | 4 |
| CIBINQO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,220 | 4 |
| JAK INHIBITOR DERM CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,860 | 3 |
| A PHASE 3 EXTENSION TRIAL OF DELTA 1 AND DELTA 2 TO EVALUATE THE LONG-TERM SAFETY OF A TWICE-DAILY TREATMENT WITH DELGOCITINIB CREAM 20 MG/G AS NEEDED FOR UP TO 36 WEEKS IN ADULT SUBJECTS WITH CHRONIC HAND ECZEMA (DELTA 3) | LEO Pharma AS | $3,135 | 3 |
| Epidemiology and patient reported outcomes in paediatric patients with atopic dermatitis | GENZYME CORPORATION | $2,750 | 5 |
| A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis | SANOFI US SERVICES INC. | $2,711 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY INVESTIGATING THE EFFICACY, SAFETY, SERUM CONCENTRATION AND BIOMARKER PROFILE OF DUPILUMAB ADMINISTERED TO ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $2,702 | 2 |
| DOSE-RANGING TRIAL TO EVALUATE DELGOCITINIB CREAM 1, 3, 8, AND 20 MG/G COMPARED TO DELGOCITINIB CREAM VEHICLE OVER AN 8-WEEK TREATMENT PERIOD IN ADULT SUBJECTS WITH ATOPIC DERMATITIS. | LEO Pharma AS | $1,995 | 2 |
| SOLO 1; SOLO 2 | SANOFI-AVENTIS U.S. LLC | $1,862 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL- GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS | Regeneron Pharmaceuticals, Inc. | $1,544 | 5 |
| A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | GENZYME CORPORATION | $1,250 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy, Safety, Serum Concentration and Biomarker Profile of Dupilumab Administered to Adult Patients With Mode | SANOFI-AVENTIS U.S. LLC | $985.11 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB MONOTHERAPY IN PATIENTS >=12 TO <18 YEARS OF AGE, WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $841.65 | 1 |
| M16-047 | AbbVie Inc. | $826.00 | 1 |
| A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients 12 to 18 Years of Age, With Moderate-to-severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $765.05 | 2 |
| A Real-world Study Evaluating Adequacy of Existing Systemic Treatment for Patients with Moderate-to-Severe Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $694.86 | 1 |
| AD QUEST (Optum) | SANOFI-AVENTIS U.S. LLC | $659.59 | 2 |
| AD-QUEST baseline survey + claims interim data manuscript | SANOFI-AVENTIS U.S. LLC | $657.30 | 1 |
| A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (AD-QUEST): 6-month survey data on flares | SANOFI-AVENTIS U.S. LLC | $646.53 | 2 |
| HEALTH ECONOMICS AND OUTCOMES RESEARCH HEOR | Regeneron Pharmaceuticals, Inc. | $484.62 | 1 |
| A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (AD-QUEST): baseline treatment Patterns and unmet needs assessment | SANOFI-AVENTIS U.S. LLC | $390.06 | 2 |
| A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) | AbbVie Inc. | $336.58 | 5 |
| Epidemiology and patient reported outcomes in paediatric patients with atopic dermatitis | SANOFI US SERVICES INC. | $250.00 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE IN PATIENTS WITH ATOPIC DERMATITIS | Regeneron Pharmaceuticals, Inc. | $226.26 | 1 |
| OPTUM/AD-QUEST | SANOFI-AVENTIS U.S. LLC | $204.95 | 1 |
| Persistence to Dupilumab in Adults with Atopic Dermatitis | SANOFI-AVENTIS U.S. LLC | $152.19 | 1 |
| A real-world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate-to-severe Atopic Dermatitis (AD-QUEST): 6-month claims results | SANOFI-AVENTIS U.S. LLC | $145.53 | 1 |
| AD-QUEST 6 month claims AMCP abstract | SANOFI-AVENTIS U.S. LLC | $134.67 | 1 |
| AD-QUEST 6 month survey SID abstract | SANOFI-AVENTIS U.S. LLC | $134.67 | 1 |
| AD-QUEST | SANOFI-AVENTIS U.S. LLC | $66.55 | 1 |
| A Real-World Study Evaluating adeQUacy of Existing Systemic Treatments for Patients with Moderate-To-Severe Atopic Dermatitis (QUEST-AD): Baseline Treatment Patterns and Unmet Needs Assessment | SANOFI-AVENTIS U.S. LLC | $50.40 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 19 | 28 | $6,720 | $2,337 |
| 2022 | 2 | 41 | 823 | $26,140 | $8,308 |
| 2021 | 5 | 77 | 1,201 | $39,605 | $14,169 |
| 2020 | 3 | 47 | 973 | $31,030 | $9,441 |
Total Patients
184
Total Services
3,025
Medicare Billing
$34,255
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 19 | 28 | $6,720 | $2,337 | 34.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 29 | 44 | $10,560 | $4,276 | 40.5% |
| 95044 | Test for allergy using skin patch | Office | 2022 | 12 | 779 | $15,580 | $4,032 | 25.9% |
| 95044 | Application of allergenic extract skin patch with reaction analysis | Office | 2021 | 14 | 1,120 | $22,400 | $6,111 | 27.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 33 | $7,920 | $3,742 | 47.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 13 | 15 | $4,725 | $2,517 | 53.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 15 | 18 | $3,060 | $1,252 | 40.9% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 11 | 15 | $1,500 | $547.54 | 36.5% |
| 95044 | Application of allergenic extract skin patch with reaction analysis | Office | 2020 | 11 | 915 | $18,300 | $4,742 | 25.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 21 | 41 | $9,840 | $3,597 | 36.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 15 | 17 | $2,890 | $1,102 | 38.1% |
About Jonathan Silverberg, MD, PHD, MPH
Jonathan Silverberg, MD, PHD, MPH is a Dermatology healthcare provider based in Washington, District of Columbia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/08/2009. The National Provider Identifier (NPI) number assigned to this provider is 1831325521.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Jonathan Silverberg, MD, PHD, MPH has received a total of $4.9M in payments from pharmaceutical and medical device companies, with $791,460 received in 2024. These payments were reported across 3,127 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.2M).
As a Medicare-enrolled provider, Silverberg has provided services to 184 Medicare beneficiaries, totaling 3,025 services with total Medicare billing of $34,255. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Dermatology
- Location Washington, DC
- Active Since 06/08/2009
- Last Updated 08/15/2019
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1831325521
Products in Payments
- DUPIXENT (Biological) $1.2M
- RINVOQ (Biological) $541,169
- DUPIXENT DUPILUMAB INJECTION (Biological) $311,717
- DUPIXENT (Drug) $297,797
- CIBINQO (Drug) $275,519
- EUCRISA (Drug) $159,131
- ATOPIC DERMATITIS - DISEASE (Drug) $106,753
- ADBRY (Biological) $70,236
- OLUMIANT (Drug) $54,348
- QBREXZA (Drug) $27,664
- NO PRODUCT DISCUSSED (Drug) $22,750
- Enbrel (Biological) $16,070
- Zoryve (Drug) $15,463
- Olumiant (Drug) $13,585
- VTAMA (Drug) $10,022
- TREMFYA (Drug) $9,784
- RINVOQ (Drug) $8,820
- OPZELURA (Drug) $8,065
- TAPINAROF (Drug) $6,400
- Otezla (Drug) $4,500
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Washington
Dr. Adam Friedman, M.d, M.D
Dermatology — Payments: $1.8M
Dermatology $1.8M
Dr. Terrence Keaney, M.d, M.D
Dermatology — Payments: $1.1M
Dermatology $1.1M
Dr. Candrice Heath, Md, MD
Dermatology — Payments: $214,277
Dermatology $214,277
Mary Ruth Buchness, Md, MD
Dermatology — Payments: $150,119
Dermatology $150,119
Dr. Todd Perkins, Md, MD
Dermatology — Payments: $117,310
Dermatology $117,310
Dr. Yolanda Holmes, Md, MD
Dermatology — Payments: $107,834
Dermatology $107,834